Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Vaishali Pharma Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹6.50Overvalued by 19.95%vs CMP ₹8.12

P/E (25.0) × ROE (6.0%) × BV (₹5.29) × DY (2.00%)

₹5.03Overvalued by 38.05%vs CMP ₹8.12
MoS: -61.4% (Negative)Confidence: 45/100 (Moderate)Models: 2 Fair, 4 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹6.0134%Over (-26%)
Graham NumberEarnings₹3.0925%Over (-61.9%)
Net Asset ValueAssets₹5.2911%Over (-34.9%)
Earnings YieldEarnings₹0.8011%Over (-90.1%)
ROCE CapitalReturns₹8.3911%Fair (+3.3%)
Revenue MultipleRevenue₹7.588%Fair (-6.7%)
Consensus (6 models)₹5.03100%Overvalued
Key Drivers: Wide model spread (₹1–₹8) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -7.4%

*Investments are subject to market risks

Analyst Summary

Vaishali Pharma Ltd operates in the Industry not found segment, NSE: Code | BSE: Code, current market price is ₹8.12, market cap is 106 Cr.. At a glance, stock P/E is 25.0, ROE is 6.02 %, ROCE is 8.90 %, book value is 5.29, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹5.03, around 38.1% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹99 Cr versus the prior period change of 15.1%, while latest net profit is about ₹1 Cr with a prior-period change of 0.0%. The 52-week range shown on this page is 12.8/4.75, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisVaishali Pharma Ltd. is a Public Limited Listed company incorporated on 25/03/2008 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L…

This summary is generated from the stock page data available for Vaishali Pharma Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

48
Vaishali Pharma Ltd scores 48/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health61/100 · Moderate
ROCE 8.9% AverageROE 6.0% AverageD/E 0.71 ModerateInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money35/100 · Weak
Promoter decreased by 1.07% Caution
Earnings Quality30/100 · Weak
OPM contracting (11% → 2%) DecliningWorking capital: 231 days Capital intensive
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +15% YoY GrowingProfit (4Q): -223% YoY Declining
Industry Rank55/100 · Moderate
P/E 25.0 vs industry 341.3 Cheaper than peersROCE 8.9% vs industry 12.3% AverageROE 6.0% vs industry 30.0% Below peers3Y sales CAGR: 9% Moderate

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: August 25, 2026, 8:36 am

Market Cap 106 Cr.
Current Price 8.12
Intrinsic Value₹5.03
High / Low 12.8/4.75
Stock P/E25.0
Book Value 5.29
Dividend Yield0.00 %
ROCE8.90 %
ROE6.02 %
Face Value 2.00
PEG Ratio-3.37

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Vaishali Pharma Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Vaishali Pharma Ltd 106 Cr. 8.12 12.8/4.7525.0 5.290.00 %8.90 %6.02 % 2.00
Aayush Food And Herbs Ltd 106 Cr. 21.7 92.8/21.526.0 2.530.12 %36.1 %39.1 % 1.00
Denis Chem Lab Ltd 100 Cr. 72.3 103/56.112.6 66.03.46 %14.0 %9.52 % 10.0
Atlanta Ltd 207 Cr. 25.427.1/10.3 6.430.00 %0.67 %% 2.00
Alfred Herbert (India) Ltd 221 Cr. 2,865 3,974/2,2006.20 7,4360.17 %11.7 %10.2 % 10.0
Industry Average10,928.55 Cr238.86341.32229.260.33%12.31%29.95%8.90

All Competitor Stocks of Vaishali Pharma Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 20.0926.2413.4212.5727.9032.4018.0820.7927.9132.2523.7533.4524.65
Expenses 16.5325.4611.119.9224.9539.1915.7318.3726.5538.2922.3832.0623.09
Operating Profit 3.560.782.312.652.95-6.792.352.421.36-6.041.371.391.56
OPM % 17.72%2.97%17.21%21.08%10.57%-20.96%13.00%11.64%4.87%-18.73%5.77%4.16%6.33%
Other Income 0.530.530.360.300.470.910.420.711.071.000.840.840.89
Interest 0.420.540.430.470.430.400.380.380.380.440.330.400.51
Depreciation 0.120.150.120.120.120.140.120.120.120.120.140.170.13
Profit before tax 3.550.622.122.362.87-6.422.272.631.93-5.601.741.661.81
Tax % 25.07%29.03%25.00%27.97%26.13%-26.95%25.11%25.10%24.87%-23.39%26.44%28.31%28.18%
Net Profit 2.660.441.591.702.11-4.681.701.971.44-4.291.281.181.30
EPS in Rs 0.250.040.150.160.20-0.440.160.180.13-0.400.120.090.10

Last Updated: March 3, 2026, 1:56 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 9:10 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1219567646875605476708699114
Expenses 1189566606573595169608598116
Operating Profit 2-01332137921-2
OPM % 2%-0%1%5%4%3%2%5%9%13%2%1%-2%
Other Income 1431222222234
Interest 3333333322222
Depreciation 0000000000101
Profit before tax 10-0111016911-0
Tax % 50%-7%300%32%41%37%62%26%30%25%23%34%
Net Profit 00-0111014711-1
EPS in Rs 0.380.20-0.040.150.080.070.000.100.380.630.070.08-0.09
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)0.00%0.00%-100.00%300.00%75.00%-85.71%0.00%
Change in YoY Net Profit Growth (%)0.00%0.00%-100.00%400.00%-225.00%-160.71%85.71%

Vaishali Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:0%
5 Years:11%
3 Years:9%
TTM:15%
Compounded Profit Growth
10 Years:18%
5 Years:94%
3 Years:-41%
TTM:-52%
Stock Price CAGR
10 Years:%
5 Years:24%
3 Years:8%
1 Year:-35%
Return on Equity
10 Years:7%
5 Years:8%
3 Years:6%
Last Year:2%

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: July 27, 2026, 6:00 am

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital 0.500.5037711111111112626
Reserves 331141511121630323943
Borrowings 252123181717182115131219
Other Liabilities 172518253028463424243335
Total Liabilities 46494564696686827980110123
Fixed Assets 211111112222
CWIP -0-0-000000110-0
Investments 000000000005
Other Assets 44484362676484807677107116
Total Assets 46494564696686827980110123

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity + -450-9432111-180
Cash from Investing Activity + 2311-0-0-0-101-0-5
Cash from Financing Activity + 2-8-18-4-3-20-2-1185
Net Cash Flow -00-000001-010-0
Free Cash Flow -550-10432011-18-0
CFO/OP 1,252%842%16%-326%212%433%78%31%28%185%-3,104%19%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow2.00-25.00-20.00-20.00-15.00-15.00-16.00-15.00-14.00-6.00-11.00-11.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 116133221214240240286453282281209172
Inventory Days 261320711565420220
Days Payable 996614510013613016932116312095116
Cash Conversion Cycle 43809612111511512313712218111677
Working Capital Days 599825149798124146111208169231
ROCE %19%14%13%16%13%10%7%10%19%22%6%5%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Jul 2026
Promoters 26.62%26.32%26.32%26.32%26.32%26.32%26.32%26.32%31.61%31.61%31.61%30.54%
Public 73.38%73.68%73.68%73.67%73.68%73.68%73.68%73.68%68.39%68.39%68.39%69.46%
No. of Shareholders 9,1819,3909,47918,98327,54628,87428,68227,75227,14826,53426,67126,697

Shareholding Pattern Chart

No. of Shareholders

Vaishali Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.0010.0010.0010.0010.00
Basic EPS (Rs.) 0.060.686.263.820.99
Diluted EPS (Rs.) 0.060.645.913.820.99
Cash EPS (Rs.) 0.091.146.744.251.40
Book Value[Excl.RevalReserv]/Share (Rs.) 4.9833.4131.2624.9921.26
Book Value[Incl.RevalReserv]/Share (Rs.) 4.9833.4131.2624.9921.26
Revenue From Operations / Share (Rs.) 7.5980.4966.0571.8950.99
PBDIT / Share (Rs.) 0.252.9610.778.204.21
PBIT / Share (Rs.) 0.212.4810.297.763.81
PBT / Share (Rs.) 0.090.868.395.431.33
Net Profit / Share (Rs.) 0.060.676.263.810.99
PBDIT Margin (%) 3.323.6716.3011.398.26
PBIT Margin (%) 2.833.0815.5810.797.46
PBT Margin (%) 1.231.0712.697.552.61
Net Profit Margin (%) 0.820.839.475.301.94
Return on Networth / Equity (%) 1.252.0020.0215.264.66
Return on Capital Employeed (%) 4.025.6823.1727.5714.94
Return On Assets (%) 0.740.898.364.921.21
Long Term Debt / Equity (X) 0.060.100.150.110.18
Total Debt / Equity (X) 0.170.350.410.780.71
Asset Turnover Ratio (%) 1.041.090.860.900.70
Current Ratio (X) 2.612.252.271.471.37
Quick Ratio (X) 2.492.242.171.461.36
Inventory Turnover Ratio (X) 38.160.000.000.000.00
Interest Coverage Ratio (X) 2.081.835.663.521.70
Interest Coverage Ratio (Post Tax) (X) 1.521.414.292.641.40
Enterprise Value (Cr.) 173.94161.15166.5589.1749.85
EV / Net Operating Revenue (X) 1.761.872.391.180.92
EV / EBITDA (X) 52.7850.8214.6610.3211.22
MarketCap / Net Operating Revenue (X) 1.661.742.210.920.63
Price / BV (X) 2.534.194.672.651.53
Price / Net Operating Revenue (X) 1.661.742.210.920.63
EarningsYield 0.000.000.040.050.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

[display_about_company_data title=”About the Company – Qualitative Analysis”]

FAQ

What is the intrinsic value of Vaishali Pharma Ltd and is it undervalued?

As of 04 September 2026, Vaishali Pharma Ltd's intrinsic value is ₹5.03, which is 38.05% lower than the current market price of ₹8.12, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (6.02 %), book value (₹5.29), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Vaishali Pharma Ltd?

Vaishali Pharma Ltd is trading at ₹8.12 as of 04 September 2026, with a FY2026-2027 high of ₹12.8 and low of ₹4.75. The stock is currently in the middle of its 52-week range. Market cap stands at ₹106 Cr..

How does Vaishali Pharma Ltd's P/E ratio compare to its industry?

Vaishali Pharma Ltd has a P/E ratio of 25.0, which is below the industry average of 341.32. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Vaishali Pharma Ltd financially healthy?

Key indicators for Vaishali Pharma Ltd: ROCE of 8.90 % is on the lower side compared to the industry average of 12.31%; ROE of 6.02 % is below ideal levels (industry average: 29.95%). Dividend yield is 0.00 %.

Is Vaishali Pharma Ltd profitable and how is the profit trend?

Vaishali Pharma Ltd reported a net profit of ₹1 Cr in Mar 2025 on revenue of ₹99 Cr. Compared to ₹4 Cr in Mar 2022, the net profit shows a declining trend.

Does Vaishali Pharma Ltd pay dividends?

Vaishali Pharma Ltd has a dividend yield of 0.00 % at the current price of ₹8.12. The company is currently not paying meaningful dividends.

Last Updated: August 25, 2026, 8:36 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: | NSE:
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vaishali Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports